Madrigal Pharmaceuticals Stock Market Value
| MDGL Stock | USD 441.68 15.83 3.72% |
| Symbol | Madrigal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.85) | Revenue Per Share | Quarterly Revenue Growth 2.108 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Madrigal Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Madrigal Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Madrigal Pharmaceuticals.
| 12/04/2025 |
| 03/04/2026 |
If you would invest 0.00 in Madrigal Pharmaceuticals on December 4, 2025 and sell it all today you would earn a total of 0.00 from holding Madrigal Pharmaceuticals or generate 0.0% return on investment in Madrigal Pharmaceuticals over 90 days. Madrigal Pharmaceuticals is related to or competes with Avidity Biosciences, Jazz Pharmaceuticals, Moderna, Caris Life, Rhythm Pharmaceuticals, Abivax SA, and Bio Techne. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializa... More
Madrigal Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Madrigal Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Madrigal Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 19.67 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 3.41 |
Madrigal Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Madrigal Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Madrigal Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Madrigal Pharmaceuticals historical prices to predict the future Madrigal Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.51) |
Madrigal Pharmaceuticals March 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.50) | |||
| Mean Deviation | 1.77 | |||
| Coefficient Of Variation | (578.59) | |||
| Standard Deviation | 2.67 | |||
| Variance | 7.15 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.51) | |||
| Maximum Drawdown | 19.67 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 3.41 | |||
| Skewness | (0.51) | |||
| Kurtosis | 5.02 |
Madrigal Pharmaceuticals Backtested Returns
Madrigal Pharmaceuticals has Sharpe Ratio of -0.18, which conveys that the firm had a -0.18 % return per unit of risk over the last 3 months. Madrigal Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Madrigal Pharmaceuticals' Mean Deviation of 1.77, standard deviation of 2.67, and Risk Adjusted Performance of (0.12) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.92, which conveys possible diversification benefits within a given portfolio. Madrigal Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Madrigal Pharmaceuticals is expected to follow. At this point, Madrigal Pharmaceuticals has a negative expected return of -0.49%. Please make sure to verify Madrigal Pharmaceuticals' potential upside, and the relationship between the total risk alpha and daily balance of power , to decide if Madrigal Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.66 |
Good predictability
Madrigal Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Madrigal Pharmaceuticals time series from 4th of December 2025 to 18th of January 2026 and 18th of January 2026 to 4th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Madrigal Pharmaceuticals price movement. The serial correlation of 0.66 indicates that around 66.0% of current Madrigal Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 638.71 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Madrigal Pharmaceuticals Correlation, Madrigal Pharmaceuticals Volatility and Madrigal Pharmaceuticals Performance module to complement your research on Madrigal Pharmaceuticals. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Madrigal Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.